Navigation Links
RoosterBio Submits U.S. FDA Master Files for CliniControl™ Line of Human Mesenchymal Stem/Stromal Cell Products
Date:11/13/2018

RoosterBio Inc, a leading supplier of human Mesenchymal Stem/Stromal Cell (hMSC) working cell banks and hMSC-specific bioprocess systems, announces today it has submitted a U.S. Food and Drug Administration (FDA) Type II Master File (MF) for its CliniControl™ line of cGMP hMSC working cell banks. This MF complements the MF for the CliniControl RoosterNourish™-MSC-CC bioprocess media that was filed in 2017. The MFs contain confidential information on the products including their chemistry, manufacture, and controls. This enables RoosterBio to protect proprietary product information yet allows the FDA to review the information in support of an investigator’s submission. Upon request, RoosterBio will grant a customer authorization to cross reference the stated MF(s) to support their own regulatory filing, such as an Investigational New Drug (IND) application to the FDA. INDs are filed with the FDA prior to beginning clinical evaluation of new therapeutic products in human subjects.

“RoosterBio’s regulatory filings demonstrate our ongoing commitment to support customers conducting clinical trials using our innovative hMSC systems,” said Kathy Williams, Vice President of Quality Assurance and Regulatory Affairs at RoosterBio.

To date, these are the first hMSC products to be commercialized as off-the-shelf, cGMP-compliant hMSC working cell banks and bioprocess media systems with accompanying Master Files. RoosterBio’s CliniControl products are designed to radically simplify the process of clinical translation for Regenerative Medicine companies that utilize hMSCs within their manufacturing process.

The use of hMSCs in clinical trials is expanding rapidly. There are currently more than 50 late-stage clinical trials listed at ClinicalTrials.gov involving hMSC therapeutics, and there are several marketed hMSC products worldwide with several more expected to hit the market in the coming years. A 2017 report has estimated the WW stem cell market at more than $5 billion currently with growth to over $9.5 billion by 2025.

“RoosterBio’s CliniControl products with accompanying MFs represent a significant company milestone and is a meaningful advancement for the industry. The regulatory work that we have taken out of our customers’ hands demonstrates our dedication to reducing the time it takes to get life-saving regenerative medicine products into the clinic, and onto the market,” said Jon Rowley, Ph.D., Founder and Chief Product Officer for RoosterBio.

About RoosterBio, Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).

Read the full story at https://www.prweb.com/releases/roosterbio_submits_u_s_fda_master_files_for_clinicontrol_line_of_human_mesenchymal_stem_stromal_cell_products/prweb15909351.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine news :

1. RoosterBio and GenCure expand collaboration to provide end-to-end solutions for hMSC-based therapies
2. RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing
3. CELLINK and RoosterBio announce partnership launching industry’s first living cellular bioink kits
4. NACDS Submits Comments to President’s Commission on Combating Drug Addiction and the Opioid Crisis
5. The Alliance for Regenerative Medicine Submits Comments to FDA’s Draft Guidance on Minimal Manipulation
6. Sanuthera Submits Serenity Device to FDA for 510(k) Clearance
7. RestorationMaster Client ServiceMaster by T.A. Russell Hosted 5th Annual Golf Tournament to Raise Funds for City of Hope
8. Founder of Global Zen Consciousness Conference, Zen Master DeRu will answer questions pertaining to 21st-century challenges at Harvard University
9. FDAnews Announces — New Management Report — ClinicalTrials.gov: Mastering New Reporting Rules
10. Master P's GMGB Co-Ed Professional Basketball League Makes History
11. Master Supplements Relaunches Quality Control Database
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... ... plans participating in Medicare Advantage, Medicaid, and Marketplace programs is pleased to announce ... Electronic Health Records (EHR) integration at the point of care to ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... client engagement options for human services providers worldwide, has been awarded a California ... program streamlines the procurement process for state and local government agencies in California ...
(Date:7/17/2019)... ... July 17, 2019 , ... The Coalition of Medication-Assisted Treatment ... seven of its member Opioid Treatment Programs (OTPs) at 12 locations are participating ... virus (HCV) with the goal of achieving better outcomes through telemedicine. The study, ...
(Date:7/13/2019)... ... ... Dr. Rupa Jolly, dentist and wife of Dr. Tarun Jolly of Tarun ... New Orleanians in 2019. She joins more than 20 other locals on the list, ... on the New Orleans community. , Combining their backgrounds in science and medicine, Dr. ...
(Date:7/13/2019)... CHARLOTTE, N.C. (PRWEB) , ... July 12, 2019 ... ... brand (NYSE American: YCBD), has been named a “Brand to Watch” by Brightfield ... Brightfield Group ranked cbdMD in the top 10 of domestic CBD companies in ...
Breaking Medicine News(10 mins):
(Date:7/19/2019)... CHICAGO (PRWEB) , ... July 19, 2019 , ... ... Meeting, September 11-13, in Phoenix, will provide strategies to keep pathologists, laboratory professionals ... stewardship techniques to improve outcomes and enhance patient care. , Renowned Speakers ...
(Date:7/19/2019)... , ... July 19, 2019 , ... Robinson Pharma, Inc., ... means that the facilities was audited by the Safe Quality Food (SQF) Institute using ... the SQF Food Safety Code for Manufacturing, Edition 8. , The SQF Certification program ...
(Date:7/18/2019)... ... July 18, 2019 , ... ... needs in the field of urology, today announced that Timothy Lesser, MD, Skyline ... The designation recognizes that Dr. Lesser has achieved a high level of training ...
Breaking Medicine Technology: